Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Sagent Announces Launch of Travoprost Ophthalmic Solution, USP

Summary by PR Newswire
/PRNewswire/ -- Sagent Pharmaceuticals ("Sagent"), a leading provider of pharmaceuticals to the US market, today announced its entry into the ophthalmic market...

11 Articles

Farm Talk NewspaperFarm Talk Newspaper
+9 Reposted by 9 other sources
Center

Sagent Announces Launch of Travoprost Ophthalmic Solution, USP

Travoprost represents the first ophthalmic solution in Sagent's growing product portfolio

·Parsons, United States
Read Full Article
ophthalmologytimes.comophthalmologytimes.com

Sagent Pharmaceuticals enters ophthalmic market, launches travoprost ophthalmic solution, USP 0.004%

Travoprost is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

PR Newswire broke the news in United States on Monday, September 15, 2025.
Sources are mostly out of (0)

Similar News Topics

Borger icon

Borger

News
For You
SearchBlindspotLocal